# US 2021/0275666 A1 · Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275666 A1
- Document ID: US20210275666A1
- Status: Published application
- Kind: A1
- Application number: 17/193,631
- Filed: 2021-03-05
- Published: 2021-09-09
- Earliest claimed: 2020-03-06
- Assignees: Incyte Corporation
- Applicants: Incyte Corporation
- Inventors: Jonathan Rios-Doria; Holly K. Koblish
- Web page: https://patentgrep.com/patent/US20210275666A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/52: Constant or Fc region; Isotype
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

## Claims

### Claim 1

A method of treating cancer in a patient, comprising administering to said patient:
(i) Compound 1, having the structure:
or a pharmaceutically acceptable salt thereof; and
(ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody comprises (ii-1) a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3; and (ii-2) a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3; wherein:
(a) the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);
(b) the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7);
(c) the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8);
(d) the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);
(e) the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and
(f) the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11).

### Claim 2 (depends on 1)

The method of claim 1, wherein Compound 1 and the antibody are administered simultaneously.

### Claim 3 (depends on 1)

The method of claim 1, wherein Compound 1 and the antibody are administered sequentially.

### Claim 4 (depends on 1)

The method of claim 1, wherein Compound 1 is administered orally.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment is administered via intravenous administration.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment is administered at a dose of 375 mg once every 3 weeks.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment is administered at a dose of 500 mg once every 4 weeks.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment is administered at a dose of 750 mg once every 4 weeks.

### Claim 9 (depends on 1)

The method of claim 1, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4.

### Claim 10 (depends on 1)

The method of claim 1, wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5.

### Claim 11 (depends on 1)

The method of claim 1, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5.

### Claim 12 (depends on 1)

The method of claim 1, wherein:
(a) the antibody comprises an Fc Region and a Hinge Domain;
(b) the Fc Region and the Hinge Domain are of the IgG4 type; and
(c) the Hinge Domain comprises a stabilizing mutation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2.

### Claim 14 (depends on 1)

The method of claim 1, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

### Claim 15 (depends on 1)

The method of claim 1, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

### Claim 16 (depends on 1)

The method of claim 1, wherein the antibody comprises an Fc Region that is of the IgG1 type.

### Claim 17 (depends on 1)

The method of claim 1, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:13.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antibody comprises a light chain and a heavy chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:13 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antibody is a humanized antibody.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, anal cancer, Merkel cell carcinoma, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

### Claim 21 (depends on 1)

The method of claim 1, wherein the cancer is selected from sarcoma, head and neck cancer, melanoma, and non-small cell lung cancer.
